Dong-A ST introduces candidate substance technology

for immuno-cancer drugs a down payment of 5 billion won

Licensee Agreement with Kanaph Theraputics

Up to 200 billion won in milestones and commercialization

Global joint development of immuno-cancer drugs under the mechanism of double fusion antibodies and acquisition of exclusive sales rights Dong-A ST announced on the 21st that it has signed a license agreement with Kanaph Therapeutics to license candidate substances for immuno-cancer drugs under the dual fusion antibody mechanism.

 

Dong-AST will introduce global joint research and development and exclusive sales rights of preclinical immuno-cancer drug candidates held by Kanaph Therapeutics, a domestic pharmaceutical bio-venture.

 

Dong-AST will pay Kanaph 5 billion won in advance and up to 18 billion won in additional payments depending on the development milestone.

 

It also plans to pay up to 180 billion won more depending on sales if it succeeds in commercialization.

 

Royalty is separate and will be paid at a certain rate according to the sales profit after the product is released.

 

According to Dong-AST, the substance is an antibody and cytokine fusion protein.

 

It is a mechanism to activate immunity by transferring cytokines specifically to tumors using antibodies to proteins expressed in the tumor microenvironment.

 

At this time, cytokines are not delivered to normal tissues, so side effects of systemic immune activity can be prevented.